Viropro Stock Analysis

Viropro Stock Analysis Notes

The company has Price to Book (P/B) ratio of 1.17. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Viropro had not issued any dividends in recent years. The entity had 1:12.14 split on the 26th of November 2003. Viropro Inc., through its subsidiaries, engages in the contract research, development, and manufacture of biotherapeutic proteins for the treatment of various diseases. Viropro Inc. has collaboration agreement with Oncobiologics, Inc. to manufacture and commercialize monoclonal antibody products. VIROPRO INC operates under Biotechnology classification in the United States and is traded on PNK Exchange. For more information please call Michelle Peake at 650 300 5190 or visit https://www.viropro.net.

Viropro Investment Alerts

Viropro Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 18.32 K.

Viropro Profitablity

Management Efficiency

As of the 10th of February 2026, Return On Tangible Assets is likely to drop to -4.04. In addition to that, Return On Capital Employed is likely to grow to -0.58. At this time, Viropro's Total Assets are very stable compared to the past year. As of the 10th of February 2026, Fixed Asset Turnover is likely to grow to 16.32, while Net Tangible Assets are likely to drop (508.4 K). Viropro's management efficiency ratios could be used to measure how well Viropro manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Viropro, as well as the relationship between them.

Viropro Price Movement Analysis

Viropro Insider Trading Activities

Viropro Outstanding Bonds

Viropro Bond Ratings

Viropro financial ratings play a critical role in determining how much Viropro have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Viropro's borrowing costs.

Viropro Debt to Cash Allocation

Viropro currently holds 175.56 K in liabilities with Debt to Equity (D/E) ratio of 0.57, which is about average as compared to similar companies. Note, when we think about Viropro's use of debt, we should always consider it together with its cash and equity.

Viropro Total Assets Over Time

Viropro Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Viropro uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Viropro Debt Ratio

7.1

It appears that most of the Viropro's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Viropro's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Viropro, which in turn will lower the firm's financial flexibility.

Viropro Corporate Bonds Issued

Stock analysis is the technique used by a trader or investor to examine and evaluate how Viropro prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Viropro shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Viropro. By using and applying Viropro Stock analysis, traders can create a robust methodology for identifying Viropro entry and exit points for their positions.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viropro. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Viropro Stock, please use our How to Invest in Viropro guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Understanding Viropro requires distinguishing between market price and book value, where the latter reflects Viropro's accounting equity. The concept of intrinsic value - what Viropro's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Viropro's price substantially above or below its fundamental value.

Please note, there is a significant difference between Viropro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Viropro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Viropro's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.